Display options
Cite
Zhou QY, Yang HM, Liu JX, et al. MicroRNA-497 induced by Clonorchis sinensis enhances the TGF-β/Smad signaling pathway to promote hepatic fibrosis by targeting Smad7. Parasit Vectors. 2021;14(1):472doi: 10.1186/s13071-021-04972-3.
Zhou, Q. Y., Yang, H. M., Liu, J. X., Xu, N., Li, J., Shen, L. P., Zhang, Y. Z., Koda, S., Zhang, B. B., Yu, Q., Chen, J. X., Zheng, K. Y., & Yan, C. (2021). MicroRNA-497 induced by Clonorchis sinensis enhances the TGF-β/Smad signaling pathway to promote hepatic fibrosis by targeting Smad7. Parasites & vectors, 14(1), 472. https://doi.org/10.1186/s13071-021-04972-3
Zhou, Qian-Yang, et al. "MicroRNA-497 induced by Clonorchis sinensis enhances the TGF-β/Smad signaling pathway to promote hepatic fibrosis by targeting Smad7." Parasites & vectors vol. 14,1 (2021): 472. doi: https://doi.org/10.1186/s13071-021-04972-3
Zhou QY, Yang HM, Liu JX, Xu N, Li J, Shen LP, Zhang YZ, Koda S, Zhang BB, Yu Q, Chen JX, Zheng KY, Yan C. MicroRNA-497 induced by Clonorchis sinensis enhances the TGF-β/Smad signaling pathway to promote hepatic fibrosis by targeting Smad7. Parasit Vectors. 2021 Sep 14;14(1):472. doi: 10.1186/s13071-021-04972-3. PMID: 34521449; PMCID: PMC8442346.
Copy Download .nbib Format: NLM
Share it on

Parasit Vectors. 2021 Sep 14;14(1):472. doi: 10.1186/s13071-021-04972-3.

MicroRNA-497 induced by Clonorchis sinensis enhances the TGF-β/Smad signaling pathway to promote hepatic fibrosis by targeting Smad7.

Parasites & vectors

Qian-Yang Zhou, Hui-Min Yang, Ji-Xin Liu, Na Xu, Jing Li, Li-Ping Shen, Yu-Zhao Zhang, Stephane Koda, Bei-Bei Zhang, Qian Yu, Jia-Xu Chen, Kui-Yang Zheng, Chao Yan

Affiliations

  1. Jiangsu Key Laboratory of Immunity and Metabolism, Department of Pathogenic Biology and Immunology, Xuzhou Key Laboratory of Infection and Immunity, Xuzhou Medical University, Jiangsu, 221004, Xuzhou, People's Republic of China.
  2. Department of Dermatology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210011, Jiangsu, China.
  3. National Experimental Demonstration Center for Basic Medicine Education, Department of Clinical Medicine, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, People's Republic of China.
  4. National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, Key Laboratory of Parasite and Vector Biology, Ministry of Health, WHO Collaborating Center of Malaria, Schistosomiasis and Filariasis, Shanghai, 200025, People's Republic of China.
  5. Jiangsu Key Laboratory of Immunity and Metabolism, Department of Pathogenic Biology and Immunology, Xuzhou Key Laboratory of Infection and Immunity, Xuzhou Medical University, Jiangsu, 221004, Xuzhou, People's Republic of China. [email protected].
  6. National Experimental Demonstration Center for Basic Medicine Education, Department of Clinical Medicine, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, People's Republic of China. [email protected].
  7. Jiangsu Key Laboratory of Immunity and Metabolism, Department of Pathogenic Biology and Immunology, Xuzhou Key Laboratory of Infection and Immunity, Xuzhou Medical University, Jiangsu, 221004, Xuzhou, People's Republic of China. [email protected].
  8. National Experimental Demonstration Center for Basic Medicine Education, Department of Clinical Medicine, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, People's Republic of China. [email protected].

PMID: 34521449 PMCID: PMC8442346 DOI: 10.1186/s13071-021-04972-3

Abstract

BACKGROUND: Various stimuli, including Clonorchis sinensis infection, can cause liver fibrosis. Liver fibrosis is characterized by the activation of hepatic stellate cells (HSCs) with massive production of extracellular matrix (ECM). Our previous study showed that the TGF-β

METHODS: The target of miR-497 was determined by bioinformatics analysis combined with a dual-luciferase activity assay. LX-2 cells were transfected with miR-497 inhibitor and then stimulated with TGF-β

RESULTS: In the present study, the expression of miR-497 was increased in HSCs activated by TGF-β

CONCLUSIONS: The present study demonstrates that miR-497 promotes liver fibrogenesis by targeting Smad7 to promote TGF-β/Smad signaling pathway transduction both in vivo and in vitro, which provides a promising therapeutic strategy using anti-miR-497 against liver fibrosis.

© 2021. The Author(s).

Keywords: ESPs of C. sinensis; Hepatic fibrosis; Smad7; TGF-β/Smad signaling pathway; miR-497

References

  1. Nat Genet. 2005 May;37(5):495-500 - PubMed
  2. Int J Mol Med. 2018 Jul;42(1):547-556 - PubMed
  3. Mol Oncol. 2019 Dec;13(12):2663-2678 - PubMed
  4. Parasit Vectors. 2015 Feb 04;8:70 - PubMed
  5. FEBS J. 2016 Jun;283(12):2219-32 - PubMed
  6. Nat Mater. 2017 Dec;16(12):1252-1261 - PubMed
  7. Blood Adv. 2018 Mar 13;2(5):470-480 - PubMed
  8. J Histochem Cytochem. 2016 Mar;64(3):157-67 - PubMed
  9. Adv Drug Deliv Rev. 2017 Nov 1;121:27-42 - PubMed
  10. J Hepatol. 2020 Mar;72(3):519-527 - PubMed
  11. Nat Cell Biol. 2019 Jul;21(7):856-866 - PubMed
  12. Infect Dis Poverty. 2016 Jul 06;5(1):71 - PubMed
  13. BMC Genomics. 2010 Sep 28;11:521 - PubMed
  14. Hepatology. 2019 Feb;69(2):785-802 - PubMed
  15. Mol Cell. 2014 Mar 20;53(6):1031-1043 - PubMed
  16. Biochem Biophys Res Commun. 2018 Jan 29;496(1):176-183 - PubMed
  17. Nucleic Acids Res. 2019 Jan 8;47(D1):D155-D162 - PubMed
  18. Acta Trop. 2020 May;205:105307 - PubMed
  19. Parasit Vectors. 2015 Oct 24;8:559 - PubMed
  20. J Hepatol. 2007 Oct;47(4):598-607 - PubMed
  21. Methods Mol Biol. 2019;2019:143-169 - PubMed
  22. Proc Natl Acad Sci U S A. 2016 Mar 29;113(13):E1881-9 - PubMed
  23. World J Gastroenterol. 2016 Dec 28;22(48):10512-10522 - PubMed
  24. Gastroenterology. 2003 Jul;125(1):178-91 - PubMed
  25. Lab Invest. 2015 Jul;95(7):781-9 - PubMed
  26. Mol Genet Genomic Med. 2019 Oct;7(10):e00860 - PubMed
  27. Hepatology. 2015 Jun;61(6):2008-2017 - PubMed
  28. Gene. 2018 Oct 30;675:150-156 - PubMed
  29. Infect Genet Evol. 2016 Sep;43:321-8 - PubMed
  30. Clin Lab. 2012;58(5-6):393-402 - PubMed
  31. Methods Mol Biol. 2017;1559:279-296 - PubMed
  32. Int Immunopharmacol. 2019 Apr;69:126-135 - PubMed
  33. Nat Med. 2007 Nov;13(11):1324-32 - PubMed
  34. Oncotarget. 2016 Aug 23;7(34):55900-55911 - PubMed
  35. Curr Drug Targets. 2017;18(8):921-931 - PubMed
  36. Int J Clin Exp Pathol. 2019 Jun 01;12(6):1992-2000 - PubMed
  37. FASEB J. 2020 Mar;34(3):4120-4133 - PubMed
  38. J Cell Physiol. 2019 Aug;234(8):13342-13352 - PubMed
  39. RNA Biol. 2018 Feb 1;15(2):186-193 - PubMed
  40. Methods Mol Biol. 2019;1905:45-57 - PubMed
  41. Hum Gene Ther. 2010 Sep;21(9):1147-54 - PubMed
  42. Lancet. 2016 Feb 20;387(10020):800-10 - PubMed
  43. IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1-441 - PubMed
  44. Parasit Vectors. 2019 Dec 30;12(1):611 - PubMed
  45. Neoplasma. 2020 Sep;67(5):1122-1130 - PubMed

Publication Types

Grant support